ADAR1 Sends Open Letter to Keros Board of Directors Urging the Board to Engage Constructively on Strategy, Capital Allocation and Board Refreshment
Rhea-AI Summary
ADAR1 Capital Management, Keros Therapeutics' (NASDAQ: KROS) largest shareholder with a 13.3% stake, has issued an open letter to the company's Board expressing frustration over their refusal to engage in discussions about strategy and governance.
The letter criticizes the Board's lack of progress on their June 9 announcement to return $375 million in excess capital to shareholders and urges for a special dividend. ADAR1 believes Keros is significantly undervalued, citing the company's cash balance and the Takeda partnership for elritercept as key value drivers.
ADAR1 threatens to seek new director elections at the next Annual Meeting if the Board continues to refuse engagement, while warning against making strategic changes without major stockholder input.
Positive
- ADAR1 holds significant 13.3% ownership stake, showing strong investor interest
- Company has substantial cash balance and valuable Takeda partnership for elritercept
- Planned return of $375 million in excess capital to shareholders
Negative
- Board's refusal to engage with largest shareholder indicates governance concerns
- Lack of progress on promised capital return plan after two months
- Evidence of broad stockholder dissatisfaction in 2025 Annual Meeting results
- Significant stock undervaluation according to major shareholder
News Market Reaction – KROS
In the Aug 21 session, KROS gained 6.61%, reflecting a notable positive market reaction. Our momentum scanner triggered 18 alerts that day, indicating notable trading interest and price volatility. Trading volume was above average at 2.0x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
The full text of the letter is below.
Dear Members of the Board:
In July, we wrote to the Board privately to propose an in-person meeting to discuss our ideas to maximize stockholder value. We had hoped that the broad stockholder dissatisfaction evident in the results of the 2025 Annual Meeting would prompt the Board to adopt a more constructive and conciliatory approach to its engagement with investors.
Unfortunately, that hope was misplaced. Rather than welcoming the opportunity to engage with the Company's largest stockholder, Keros' management team and Board have repeatedly declined to interact with us directly and instead referred us to the Company's financial advisor.
As we have conveyed to you (and now to your financial advisor), we believe Keros is worth significantly more than the price at which its stock trades. Its valuation is supported, in our view, by the Company's large cash balance and the net present value of the Takeda partnership for elritercept, which we believe the Company should distribute to stockholders via CVR. Given the large and persistent undervaluation of the Company's stock, we would like to work collaboratively with the Board to unlock this value for all stockholders.
In furtherance of that goal, we reiterate our request to meet with the independent directors as soon as practicable. We are available to meet at the Company's headquarters in
Additionally, we are concerned by the lack of follow-through on the Company's June 9 announcement regarding the planned return of
Our strong preference is to work together with the Board to help reorient the Company's strategic direction into one that benefits all shareholders. However, should the Board continue to refuse our invitations to engage, we will seek to elect new directors at the next Annual Meeting – directors who will embrace their role as fiduciaries and are willing to at least hear the perspectives of stockholders. In the meantime, we caution the Board against making any changes to its composition or to the Company's strategy without first seeking input from its major stockholders, including ADAR1.
Keros has an opportunity to build significant long-term value for its investors, but doing so requires a Board that is willing to listen to and work constructively with its stockholders. We urge you to take this opportunity to engage with us in good faith.
Sincerely,
Daniel Schneeberger
ADAR1 Capital Management
About ADAR1 Capital Management
ADAR1 Capital Management is an SEC-registered investment manager based in
Contact:
info@adar1.com
512-254-3790
View original content:SOURCE ADAR1 Capital Management, LLC